{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-021559","form_type":"8-K","ticker":"NTLA","cik":"0001652130","company_name":"Intellia Therapeutics, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.584246+00:00","generated_at":"2026-06-22T09:20:33.827946+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Intellia Q3 net loss $113.2M; NTLA-2001 shows 93% TTR reduction, NTLA-2002 91% attack reduction","bullets":["Net loss of $113.2M in Q3 2022 widened from $71.6M in Q3 2021; cash position $848.7M.","Collaboration revenue rose to $13.3M from $7.2M; R&D expenses increased to $96.7M.","NTLA-2001: mean serum TTR reductions of 93% (0.7 mg/kg) and 92% (1.0 mg/kg) at day 28.","NTLA-2002: 25 mg dose led to 91% mean reduction in HAE attacks through 16-week observation.","Expects to initiate NTLA-2002 Phase 2 in 1H 2023; plans IND filing for NTLA-3001 in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-021559","json":"https://secwatch.observer/filing/0000950170-22-021559.json","markdown":"https://secwatch.observer/filing/0000950170-22-021559.md","text":"https://secwatch.observer/filing/0000950170-22-021559.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652130/000095017022021559/0000950170-22-021559-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652130/000095017022021559/ntla-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T09:20:33.827946+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d3682a094276b3af4c9c92986e0353ba4e4314e8","claim":"Intellia Therapeutics, Inc. reported financial results for third quarter ended September 30, 2022.","evidence_excerpt":"On November 3, 2022, Intellia Therapeutics, Inc. announced its financial results and business updates for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017022021559/0000950170-22-021559-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}